Your browser does not support iframes.
JERUSALEM--(BUSINESS WIRE)--Sep. 12, 2018--
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will host a
live audio webcast at the Morgan Stanley Global Healthcare Conference in
New York, NY.
What: Teva Presentation at the Morgan Stanley Global Healthcare
Conference in New York, NY.
Who: Michael McClellan, Chief Financial Officer
When: Friday, September 14, 2018 at 9:20am (ET)
Where: Teva's Investor Relations website at ir.tevapharm.com.
The webcast can also be accessed through the following URL: https://cc.talkpoint.com/morg007/091218a_as/?entity=140_5NHE0JF
How: Register for the event approximately 10 minutes before the
scheduled start time. An archive of the webcast will be available on
Teva's Investor Relations website.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global
leader in generic medicines, with innovative treatments in select areas,
including CNS, pain and respiratory. We deliver high-quality generic
products and medicines in nearly every therapeutic area to address unmet
patient needs. We have an established presence in generics, specialty,
OTC and API, building on more than a century-old legacy, with a fully
integrated R&D function, strong operational base and global
infrastructure and scale. We strive to act in a socially and
environmentally responsible way. Headquartered in Israel, with
production and research facilities around the globe, we employ 45,000
professionals, committed to improving the lives of millions of patients.
Learn more at www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements:
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, which
are based on management’s current beliefs and expectations and are
subject to substantial risks and uncertainties, both known and unknown,
that could cause our future results, performance or achievements to
differ significantly from that expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to:
and other factors discussed in our Annual Report on Form 10-K for the
year ended December 31, 2017, including the sections thereof captioned
"Risk Factors" and "Forward Looking Statements," and in our subsequent
quarterly reports on Form 10-Q and other filings with the Securities and
Exchange Commission, which are available at www.sec.gov
Forward-looking statements speak only as of the date on which they are
made, and we assume no obligation to update or revise any
forward-looking statements or other information contained herein,
whether as a result of new information, future events or otherwise. You
are cautioned not to put undue reliance on these forward-looking
View source version on businesswire.com: https://www.businesswire.com/news/home/20180912005834/en/
Source: Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.IR ContactsKevin
C. Mannix, 215-591-8912orRan Meir, 972 (3) 926-7516orPR
ContactsUnited StatesElizabeth DeLuca,
267-468-4329orIsraelYonatan Beker, 972 (54)